Abbott Laboratories (ABT)
| Market Cap | 197.26B |
| Revenue (ttm) | 32.22B |
| Net Income (ttm) | 3.38B |
| Shares Out | 1.77B |
| EPS (ttm) | 1.89 |
| PE Ratio | 58.86 |
| Forward PE | 25.19 |
| Dividend | $1.80 |
| Dividend Yield | 1.62% |
| Trading Day | January 15 |
| Last Price | $111.30 |
| Previous Close | $111.30 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 110.00 |
| Day's Range | 109.39 - 111.62 |
| Day's Volume | 4,480,173 |
| 52-Week Range | 61.86 - 113.96 |
Welcome to Alpha Trader. We have a special double bill today in honor of wildcard weekend coming up on the show. Eddy Elfenbein of Crossing Wall Street giving us his top five new stocks for 20...
If you sell too quickly, you'll miss out on billions of dollars in product revenue -- and share performance.
Dividends and increasing revenue mean you can count on these companies for safety and growth.
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
These stocks are as solid as they come.
Abbott Laboratories (ABT) CEO Robert Ford Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.
Abbott Labs is making its rapid Covid-19 antigen test available to schools, pharmacies and workplaces that require frequent and affordable testing.
The 2021 Market Outlook And Some New Stock Picks - Ryan Detrick And Eddy Elfenbein Join Alpha Trader
This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher speaking with LPL Financial's Ryan Detrick and Eddy Elfenbein, editor of the Crossing Wall Street blog and portfol...
Abbott (ABT) closed the most recent trading day at $111.30, moving +0.97% from the previous trading session.
All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average increase of 8.4% and a median increase of 6.6%.
The U.S. is focusing on coronavirus testing and vaccination. And that's exactly where these companies excel.
These companies are developing highly competitive vaccines and diagnostics.
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Everyone loves the dividend, but investors usually don't give enough love to the dividend hike.
Abbott (ABT) closed at $109.49 in the latest trading session, marking a +0.97% move from the prior day.
These companies are heavyweights, and they're only getting stronger.
These companies are in different industries, pay dividends, and their businesses have continued to do well this year despite the coronavirus pandemic.
A beaten-down biotech, a streaming star, and a coronavirus testing giant could be well-rounded additions to your portfolio.
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.
These are three winning stocks to put under your Christmas tree.
In the latest trading session, Abbott (ABT) closed at $108.09, marking a -0.81% move from the previous day.
Abbott's (ABT) HeartMate 3 LVAD or heart pump is an implantable device that pumps blood through the body in people whose hearts are too weak to do so naturally.
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ hea...
If you have a stack of Benjamins lying around and collecting dust, put them to good use with these stocks to buy with $5,000. The post 9 Stocks to Buy With $5,000 in Starter Money appeared fir...
Abbott Laboratories is a great company that rewarded its shareholders with great returns. The company has recently rewarded shareholders with a massive 25% dividend raise.
"FDA continues to authorize COVID-19 tests that will give more Americans access to greater testing flexibility and options," FDA Commissioner Dr. Stephen Hahn said.
The sample does not need to be sent to a lab to be processed.
Abbott Laboratories said Wednesday that its at-home BinaxNOW COVID-19 rapid COVID-19 test has been issued Emergency Use Authorization by the Food and Drug Administration. The company said Bina...
ABBOTT PARK, Ill.,, Dec. 16, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for virtually...
The test is set to be used on Abbott's (ABT) ARCHITECT and Alinity i platforms.
Abbott stock is up 23% since the start of the year and it has gained around 70% from its March lows. We believe that Abbott could offer an upside in the near term, as the company's revenues in...
Abbott (ABT) closed at $106.79 in the latest trading session, marking a -0.23% move from the prior day.
Abbott's (ABT) latest hydration solution with specifically chosen nutrients along with optimal balance of electrolytes and glucose is expected to boost immunity.
And the goodies should keep on coming.
Dividend increase announcements continue to pile up as 2020 draws to a close. The health care sector remains one of my favorite places to find stocks offering solid yields and lengthy track re...
ABBOTT PARK, Ill., Dec. 14, 2020 /PRNewswire/ -- Because supporting the immune system is top of mind for many people, Abbott (NYSE: ABT) is launching a new Pedialyte formulation specifically d...
These coronavirus leaders are great picks for different reasons.
That's a big bump, even for the habitual payout raiser.
Abbott said Friday its board has raised its quarterly dividend by 25% to 45 cents a share. The health care company has raised its dividend for 49 straight years, making it a member of the S&P ...
ABBOTT PARK, Ill., Dec. 11, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share, ref...
Solid dividends and solid businesses. Buffett likes these stocks -- and you might, too.
Abbott (ABT) closed the most recent trading day at $106.32, moving -0.45% from the previous trading session.
Our indicative theme of Covid-19 Testing Stocks- which includes the stocks of companies that produce or carry out tests for the highly infectious virus - is up by about 51% year-to-date, on an...
Last month, the stock market responded positively to the news of a potential Covid-19 vaccine. While the initial impact of the news appears to be dissipating, now may be the right time to look...
Medical company Abbott has now launched a handful of coronavirus tests, and the U.S. is paying $750 million for 150 million of one of its recently approved tests. So, is ABT stock a buy now?
Under normal circumstances, an outgoing president would congratulate the incoming administration. But we're not living in normal circumstances, which bodes well for these stocks to buy during ...
Abbott's (ABT) next-generation FreeStyle Libre 2 system aims to provide a better quality of life to diabetics in Canada at the same affordable price of the current FreeStyle Libre system.
In the latest trading session, Abbott (ABT) closed at $107.53, marking a -0.57% move from the previous day.
About ABT
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as... [Read more...]
| Industry Medical Devices | Founded 1888 |
| CEO Robert Ford | Employees 107,000 |
| Stock Exchange NYSE | Ticker Symbol ABT |
Financial Performance
In 2019, ABT's revenue was $31.90 billion, an increase of 4.34% compared to the previous year's $30.58 billion. Earnings were $3.69 billion, an increase of 55.70%.
Analyst Forecasts
According to 21 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 121.76, which is an increase of 9.40% from the latest price.